Thalidomide to Patients With Previously Untreated Multiple Myeloma

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of these are given) in addition to the ordinary chemotherapeutic drug against multiple myeloma. We will find out for how long time the patients will stay free of the disease and for how long time they will live, and can evaluate whether thalidomide is a beneficial drug against this disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Norwegian University of Science and Technology
• Collaborators: Nordic Myeloma Study Group, Germany; The Research Council of Norway
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• Patients with multiple myeloma in need of treatment

Exclusion Criteria:

• Previous treatment against multiple myeloma

• Need of high dose chemotherapy with autologous stem cell support

• Women in fertile age

• Psychiatric disease or mental reduction leading to lack of cooperation

• Lack of consent

• Life expectancy below 3 months

• Active cancer of other etiology